Get started
ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

LLY chart


Full chart

Key facts today

Eli Lilly's Phase 3 study of tirzepatide showed nearly 99% of participants stayed diabetes-free after 176 weeks, with a 94% lower risk of type 2 diabetes and an average weight loss of 22.9%.
Eli Lilly and Company is assessing the competition in weight loss drugs, especially against Amgen's monthly drug MariTide, which differs from Eli Lilly's weekly injection schedule.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪775.81 T‬ ARS
Dividend yield (indicated)
0.54%
Price to earnings Ratio (TTM)
136.759
Basic EPS (TTM)
125.249 ARS
Net income (FY)
‪1.54 T‬ ARS
Revenue (FY)
‪10.05 T‬ ARS
Shares float
—
Beta (1Y)
0.30

About Eli Lilly and Company


Sector
Health Technology
CEO
David A. Ricks
Headquarters
Indianapolis
Website
lilly.com
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFTQS8
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

LLY news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

LLY highest yielding bonds


US532457AM0
ELI LILLY 2025
Yield to maturity
6.06%
Maturity date
Jun 1, 2025
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.40%
Maturity date
Aug 14, 2064
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.39%
Maturity date
Jun 15, 2044
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.37%
Maturity date
Feb 9, 2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.34%
Maturity date
Feb 27, 2063
US532457BS6
ELI LILLY 19/39
Yield to maturity
5.32%
Maturity date
Mar 15, 2039
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054
Yield to maturity
5.32%
Maturity date
Aug 14, 2054
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053
Yield to maturity
5.30%
Maturity date
Feb 27, 2053
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054
Yield to maturity
5.24%
Maturity date
Feb 9, 2054
LLY.GG
Eli Lilly and Company 6.77% 01-JAN-2036
Yield to maturity
5.23%
Maturity date
Jan 1, 2036
US532457BU1
ELI LILLY 19/59
Yield to maturity
5.20%
Maturity date
Mar 15, 2059

Explore more bonds 

Sparks


Curated watchlists where LLY is featured.

See all sparks